Immatics NV, a clinical stage biotech company, has announced the pricing of a new share offering in the US which is expected to raise $150 million for the development of T cell receptor (TCR) therapies for cancer. The underwritten public offering of 16,250,000 ordinary shares was priced at $9.25 per share. The offering is expected to close on 15 October.
